Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from Pfizer
Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business. The acquisition, which includes products in the U.S., Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, significantly increases the size of Boehringer Ingelheim's companion animal and cattle portfolios and strengthens the company's position as a leading vaccine supplier. 
GlaxoSmithKline (GSK) announced that more than 150,000 people have received GSK's pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe which commenced last week. Additionally, over 2,000 people have received Pandemrix in clinical trials which are ongoing. To date, data have demonstrated that the H1N1 adjuvanted vaccine has a similar tolerability profile to GSK's previously EMEA approved H5N1 adjuvanted vaccine. 
The Swiss regulatory authority Swissmedic has conducted an analysis with its expert medical committee on the latest data and studies regarding the risk of venous thromboembolism (VTE) associated with oral hormonal contraceptives. The results of this analysis were announced earlier by Swissmedic.
This October marks the one-year anniversary of the international launchof the ground-breaking diabetes Conversation Map(TM) education tools. Created by Healthy Interactions, a global leader in health education, in collaboration with the International Diabetes Federation (IDF), Eli Lilly and Company and other leading diabetes experts, the unique Conversation Map(TM) education tools have been implemented in 68 countries, excluding the United States, in 31 different languages in the last 365 days. 
AstraZeneca and POZEN Inc. have submitted a Marketing Authorisation Application (MAA) in the European Union via the Decentralised Procedure (DCP) for VIMOVO™ (enteric-coated naproxen/immediate release esomeprazole magnesium, formerly known as PN 400) tablets, a product under investigation for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in patients who are at risk of developing NSAID-associated ulcers. 
Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in numerous growing therapeutic areas, a robust pipeline, premier scientific and manufacturing capabilities and a leading global presence.